Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting

Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis

(2014) S.S. Xing et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease

(2014) Alex F. Herrera et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment of chronic graft-versus-host disease with bortezomib

(2014) C.-C. S. Pai et al.   BLOOD

Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells

(2014) Han Min et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Linking the activity of bortezomib in multiple myeloma and autoimmune diseases

(2014) Zdeněk Škrott et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Coming back

(2014) Fabio Penna et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Bortezomib for the treatment of non-Hodgkin’s lymphoma

(2014) Prithviraj Bose et al.   EXPERT OPINION ON PHARMACOTHERAPY

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

(2014) Lenka Kubiczkova et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness

(2014) Alba Chacon-Cabrera et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis

(2014) Yi Xiao et al.   PLoS One

Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation

(2014) C Kao et al.   Cell Death & Disease

Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients

(2013) Nicolas Tardif et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Autophagic Degradation Contributes to Muscle Wasting in Cancer Cachexia

(2013) Fabio Penna et al.   AMERICAN JOURNAL OF PATHOLOGY

From Bortezomib to other Inhibitors of the Proteasome and Beyond

(2013) Daniela Buac et al.   CURRENT PHARMACEUTICAL DESIGN

Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice

(2013) Clara Fermoselle et al.   EXPERIMENTAL PHYSIOLOGY

Deubiquitinases in skeletal muscle atrophy

(2013) Simon S. Wing   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome

(2013) Marco Sandri   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

MG132-mediated inhibition of the ubiquitin–proteasome pathway ameliorates cancer cachexia

(2013) Liuping Zhang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

JNK and Macroautophagy Activation by Bortezomib Has a Pro-Survival Effect in Primary Effusion Lymphoma Cells

(2013) Marisa Granato et al.   PLoS One

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

(2012) J. Fang et al.   BLOOD

Development of proteasome inhibitors as research tools and cancer drugs

(2012) Alfred L. Goldberg   JOURNAL OF CELL BIOLOGY

Proteasome inhibition improves diaphragm function in an animal model for COPD

(2011) Hieronymus van Hees et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice

(2011) Annabelle Z Caron et al.   BMC MUSCULOSKELETAL DISORDERS

Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation

(2011) Changyou Li et al.   CANCER LETTERS

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Pre-cachexia in patients with stages I–III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system

(2011) C.M. Op den Kamp et al.   LUNG CANCER

Proteasome inhibitors in cancer therapy

(2011) Lisa J. Crawford et al.   Journal of Cell Communication and Signaling

Therapeutic Potential of Proteasome Inhibition in Duchenne and Becker Muscular Dystrophies

(2010) Elisabetta Gazzerro et al.   AMERICAN JOURNAL OF PATHOLOGY

Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

(2010) Dominika Nowis et al.   AMERICAN JOURNAL OF PATHOLOGY

Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells

(2010) Sudharsan Periyasamy-Thandavan et al.   Autophagy

Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse

(2010) Paola Aulino et al.   BMC CANCER

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients

(2010) Maurizio Muscaritoli et al.   Internal and Emergency Medicine

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

(2010) Guido Cavaletti et al.   LEUKEMIA & LYMPHOMA

The Beclin 1–VPS34 complex – at the crossroads of autophagy and beyond

(2010) Sarah F. Funderburk et al.   TRENDS IN CELL BIOLOGY

Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction

(2009) G. S. Supinski et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice

(2009) A. Bonetto et al.   CURRENT CANCER DRUG TARGETS

Muscle myostatin signalling is enhanced in experimental cancer cachexia

(2008) P. Costelli et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Muscle wasting in diabetic and in tumor-bearing rats: Role of oxidative stress

(2007) Raffaella Mastrocola et al.   FREE RADICAL BIOLOGY AND MEDICINE